Difference between revisions of "Part:BBa K1166004"

Latest revision as of 13:42, 21 October 2021

sTRAIL

Contains the T7 expression cassette for a soluble part of TRAIL with an N-terminal histidine tag (x6) to enhance its purification. It is known to cause apoptosis in various cancer cell lines with minimal cytotoxicity toward normal cells (Walczak, et al., 1999).

TRAIL (TNF Related Apoptosis Inducing Ligand) induces apoptosis by binding to two death receptor domains, TRAIL-R1(DR4) and TRAIL-R2(DR5) (Schneider, et al., 1997). The binding of TRAIL triggers the trimerization of the death receptors that recruit and activate FADD a death domain-containing protein, FADD then recruits and activates caspase-8, leading to the formation of the death-inducing signaling complex (DISC) (Zhang L, et al., 2005).

Results: Therapeutic proteins

Expression of therapeutic proteins

The presence of the therapeutic proteins TRAIL and TAT-APOPTIN in cell lysates was confirmed by Western Blot analysis. Protein samples were obtained from 2 different batches of Escherichia coli BL21 (DE3) cultures, from both the soluble and insoluble products of the sonicated culture.

Figure 1: Western Blot, probed with anti-His6x antibody HRP conjugated. Protein samples were recovered from soluble fractions of E.coli BL21 (DE3) lysates, unless otherwise stated. Lane2: Negative control (non-transformed E.coli BL21); Lane3: Positive control (previously confirmed HIS-GFP); Lane4: HIS-TAT-APOPTIN (from Batch 2, transformant 2); Lane5: HIS-TAT-APOPTIN (from Batch 2, transformant 1); Lane6: HIS-TRAIL (from Batch 2, insoluble fraction); Lane7: HIS-TRAIL (from Batch2); Lane8: Amersham High-Range Molecular Weight Marker; Lane9: HIS-TAT-APOPTIN (from Batch 1); Lane10: HIS-TRAIL (from Batch 1, insoluble fraction)

In Figure 1, we show the expression of TRAIL and TAT-APOPTIN from different cultures of E.coli BL21.

References

Schneider P, Thome M, Burns K, Bodmer JL, Hofmann K, Kataoka T, Holler N, Tschopp J. (1997). TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity. 7(6):831-6.

Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH. (1999). Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 5(2):157-63.

Zhang L, Fang B. (2005). Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther. 12(3):228-37.

Sequence and Features

Contribution From AHUT_China 2021

• Group: iGEM21_AHUT_China
• Author: Binbin Wu
• Summary: Basing on the sequence of an existing part of sTRAIL (BBa_K1166004), we have added an isoleucine zipper (ISZ) to the N-terminal of this part and constructed a new part BBa_K3981014 (pET28a-his-linker-ISZ-sTRAIL, ISZ-sTRAIL for short, Fig. 1), which could generate the trimeric form of TRAIL and increased its antitumor potential.

Fig.1 Map of ISZ-sTRAIL expression vector

1. Construction of sTRAIL and ISZ-sTRAIL vectors

Firstly, the original coding sequence of sTRAIL (BBa_K1166004) were synthesized by company, and cloned into the pET-28a (+) expression vectors. The correctness of the recombinant plasmids was verified by PCR (Fig. 2).

Fig. 2 Agarose Gel Electrophoresis of sTRAIL recombinant plasmid. M: Marker; 1: pET-28a-his-sTRAIL; 2.pET-28a(+)

Then, we designed the primers for PCR amplification of ISZ-sTRAIL gene fragments, and obtained the ISZ-sTRAIL gene (666 bp) via PCR using pET28a-his-linker-her2-linker-ISZ-sTRAIL (BBa_K3981015) as the template (Fig. 3).

Fig. 3 Agarose Gel Electrophoresis of ISZ-sTRAIL. M: Marker; 1: ISZ-sTRAIL PCR bands, the length was 666 bp

The desired ISZ-sTRAIL gene fragments were cloned into pET-28a (+) expression vectors, then the constructed recombinant plasmids were identified by double digestion with Nco I and Xho I restriction enzymes, and the band was determined to be about 666 bp (the arrow indicated in Fig. 4). Subsequently, the sequencing results of recombinant plasmids were consistent with the target gene (Fig. 5), which indicated that ISZ-sTRAIL plasmids were successfully constructed.

Fig. 4 The double digestion of ISZ-sTRAIL recombinant vectors. M: Marker; 1: the digested vectors (the arrow indicated was ISZ-sTRAIL, the length was 666 bp); 2. ISZ-sTRAIL recombinant vectors without double digestion; 3. pET-28a (+) vectors

Fig. 5 Sequencing result of ISZ-sTRAIL plasmids

2. Expression and purification of sTRAIL and ISZ-sTRAIL proteins

The correct sTRAIL and ISZ-sTRAIL vectors were transformed into E. coli BL21(DE3) respectively, and positive colonies were selected on a Luria–Bertani (LB) agar plate with kanamycin to create the engineered strains BL21(DE3)/sTRAIL and BL21(DE3)/ISZ-sTRAIL. Then, the expressions of sTRAIL and ISZ-sTRAIL were induced with 0.5-0.8 mmol/L isopropyl β-d-thiogalactopyranoside (IPTG) followed by SDS-PAGE analysis. As shown in Fig. 6 (bands 1-2) and Fig.7 (bands 1 and 3), sTRAIL and ISZ-sTRAIL proteins could be both successfully expressed under IPTG induction. Further, the sTRAIL and recombinant ISZ-sTRAIL were purified by His affinity chromatography and determined by SDS-PAGE and Coomassie brilliant blue staining. The result showed that sTRAIL and recombinant ISZ-sTRAIL proteins were purified with high purity as indicated by a significant single protein band after SDS-PAGE in Fig. 6 (band 3) and Fig.7 (band 2).

Fig. 6 SDS-PAGE analysis for sTRAIL protein expression and purification. The arrow indicated were the bands of sTRAIL. M: protein marker; 1: Negative control without IPTG induction; 2: Cell lysate with IPTG induction for 4 h at 37 ℃; 3. Purified sTRAIL protein

Fig. 7 SDS-PAGE analysis for ISZ-sTRAIL protein expression and purification. The arrow indicated were the bands of ISZ-sTRAIL. M: protein marker; 1: Negative control without IPTG induction; 2: Purified ISZ-sTRAIL protein; 3. Cell lysate with IPTG induction for 4 h at 37 ℃

3. Anti-tumor activity of sTRAIL and ISZ-sTRAIL proteins

After efficient purification of sTRAIL and ISZ-sTRAIL proteins, we tested their anti-tumor activity on MCF7 breast cancer cells. Cell morphology pictures (Fig. 8) and MTT assay (Fig. 9) showed that both sTRAIL and ISZ-sTRAIL proteins could inhibit the proliferation of MCF7 cells, and the improved part of ISZ-TRAIL demonstrated increased potential anti-proliferation activity than the original part of sTRAIL.

Fig. 8 The anti-proliferation effects of sTRAIL and ISZ-sTRAIL proteins on MCF7 breast cancer cells

Fig. 9 MTT assay of sTRAIL and ISZ-sTRAIL proteins on MCF7 cell growth

In conclusion, our results demonstrated that the function of ISZ-sTRAIL new part has been improved with higher anti-tumor activity than the original part.

Reference

[1] Yan C, Li S, Li Z, et al. Human umbilical cord mesenchymal stem cells as vehicles of CD20-specific TRAIL fusion protein delivery: a double-target therapy against non-Hodgkin's lymphoma. Mol Pharm. 2013 Jan 7; 10(1):142-51.

[2] Shah K, Tung CH, Yang K, et al. Inducible release of TRAIL fusion proteins from a proapoptotic form for tumor therapy. Cancer Res. 2004 May 1; 64(9):3236-42.